With proprietary DIAMOND AI technology streamlining target discovery, Kiromic is positioned to rapidly expand its pipeline in innovative drug discovery and precision medicine markets. The company advanced its lead program Deltacel™ (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell therapy, with a Phase 1 clinical trial for stage 4 metastatic or locally-advanced non-small cell lung cancer as of January 2025.
Cyborg Score Rationale
The company operates with approximately 18 employees as of May 2026, signaling a lean clinical-stage operation. Early clinical results show promise, but the company remains pre-revenue and faces regulatory and development execution risks in a competitive cell therapy landscape.
Top Insights
Lead program Deltacel showed 33% tumor reduction in first patient at 12-month follow-up (January 2025), achieving partial response in late-stage lung cancer.
Proprietary DIAMOND AI 2.0 platform designed for rapid target discovery in immuno-oncology, addressing a key bottleneck in cell therapy development.
Minimal headcount (18 employees as of May 2026) indicates reliance on external manufacturing, CROs, and partnerships for clinical execution.
Company leverages allogeneic (off-the-shelf) GDT approach positioning for potential cost and manufacturing advantages over autologous CAR-T competitors.
Named Competitors
CAR-T Therapies — Established CAR-T cell therapy leader with approved products
CAR-T Therapies — Leading CAR-T developer (Celgene subsidiary)
Allogeneic Cell Therapy — Immuno-oncology and cell therapy developer
Recent Developments
(January 2025) Reported favorable 12-month efficacy data for first Deltacel-01 patient with 33% tumor reduction in metastatic NSCLC; provided enrollment update on Phase 1 trial.
(May 2026) Company has approximately 18 employees across 2 continents supporting clinical development and operations.
(October 2020) Completed $15 million IPO to strengthen balance sheet and fund pipeline development.
Open the full interactive Kiromic BioPharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.